SCOTTSDALE, AZ--(Marketwired - Mar 27, 2014) - AirWare Labs Corp. (OTCQB: AIRW) today announced plans to expand manufacturing, distribution and sales of its AIR® filtered nasal products in China. Through a joint venture agreement with Eastar Industries, LLC, AirWare Labs' nasal filters will be re-branded and sold in pharmacies throughout China, offering a new line of defense against the world's highest levels of air pollution and avian flu.
Eastar Industries, a subsidiary of Eastar Chemical Corporation, focuses on Eastar's pharmaceutical and health/beauty business for China and selected Southeast Asian countries. Eastar Industries licenses patented pharmaceuticals, medical devices and unique health/beauty products from U.S. and European companies for import to China and Southeast Asia through its local joint venture partner companies.
"This joint venture with Eastar Industries is an important step in AirWare's mission to help people live healthier lives through better breathing," said Jeffrey Rassás, CEO of AirWare Labs. "Residents of China are struggling with life-threatening air pollution that impacts their health on a daily basis. AirWare's filtered nasal products are an effective and discreet alternative to the face masks many wear to combat the negative effects of polluted air."
Designed with an integrated filter media from 3M, AirWare's nasal inserts trap airborne contaminants and prevent them from entering the body through the nasal passage. The filter protects wearers from up to 90% of common particulates, 75% or more of airborne viruses, and 92% or more of plant spores and airborne pollens. Face masks, which are widely used throughout China, do not provide a complete seal against contaminants and force wearers to breathe in their own exhaled carbon dioxide.
"Residents of China are very concerned about airborne viruses, air quality and their impact on health," said Tony Chu, CEO of Eastar Industries. "AirWare's filtered nasal products provide a great solution for hundreds of millions of people looking for a way to protect themselves and their families."
China's ever-worsening air pollution problems and the spread of avian flu have been highlighted in recent media reports:
The Washington Post reported that daily levels of PM2.5, a dangerous particulate that can cause asthma, cardiovascular disease and cancer, have reached 155.2 micrograms per cubic meter of air in China's most polluted city. (The World Health Organization considers anything over 10 micrograms per cubic meter of PM2.5 to be hazardous.) By comparison, the worst U.S. city (Bakersfield, CA) measures 18.2 micrograms of PM2.5 per cubic meter.
According to a recent article in The Guardian, air pollution in urbanized northern China will shorten 500 million Chinese lives by an average of 5.5 years.
The New York Times reported in January that China had disclosed a steadily growing number of cases of the dangerous H7N9 bird flu, which killed 26 people last spring.
AirWare Labs' joint venture agreement with Eastar Industries is the latest in a series of distribution announcements. The company recently announced a licensing agreement with Breathe Active, LLC that includes a $2 million national television media campaign. In 2013 AirWare Labs announced a national rollout into 7,500 Walgreen's stores.
About AirWare Labs Corporation:
AirWare Labs Corp. [publicly traded as (OTCQB: AIRW)] provides patented and innovative technology solutions for consumer products that promote better health through breathing and enhanced wellbeing. AirWare Labs' products are marketed under the brand name of AIR®. AIR® products utilize an FDA approved medical grade silicone, molded as an intranasal Air Breathe dilator, to act as the delivery system. This AIR® microstructure enhances normal nasal airflow with every breath -- clinically proven to deliver up to 40% more oxygen.
Some AIR® products are infused with essential oils with unique healing properties including antibacterial and therapeutic defense against airborne allergens, viruses and bacteria. AIR® Allergy and Travel products provide additional defense in the form of an integrated filter media from 3M to remove microscopic particles that carry viruses, allergens and bacteria. Other AIR® specialty products help provide and performance enhancements and relief from congestion, insomnia, headaches, nausea, and snoring. For more product information, please visit: http://www.airwarelabs.com or company information visit: http://airwarelabscorp.com.
Forward-Looking Statement: The statements in this press release regarding any implied or perceived benefits from the release by AirWare Labs Corp. of its AIR ALLERGY™ product are forward-looking statements. Such statements involve risks and uncertainties, including, but not limited to, risks and effects of legal and administrative proceedings and governmental regulation, especially in a foreign country, future financial and operational results, competition, general economic conditions, and the ability to manage and continue growth.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those indicated. Important factors that could cause actual results to differ materially from the forward-looking statements we make in this news release include the introduction of new technology, market conditions and those set forth in reports or documents we file from time to time with the SEC. We undertake no obligation to revise or update such statements to reflect current events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.